# Therapeutic possibility of "Semax" for depression.

> PubMed lists PMID 18204410 in CNS spectrums as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18204410-semax:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18204410-semax/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18204410-semax-v1.json
- Content SHA-256: `7c0f2b41dffe3dac67fc39cd79a78eedff2024842320d381d6892e7a8e33aeb3`

## Claims and source pins

### Headline

Therapeutic possibility of "Semax" for depression. ([`pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489`](#source-pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489))

### Summary

PubMed lists PMID 18204410 in CNS spectrums as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489`](#source-pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489))

### Paragraph 1

PubMed lists PMID 18204410 in CNS spectrums as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489`](#source-pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489`](#source-pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489))

## Sources

<a id="source-pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489"></a>
- **Therapeutic possibility of "Semax" for depression. · retained source version 1:2026-01-28:current:bf119eab6489c747b99de8df515ca73a0e778454eff4144564731b2ebbc2fa67** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18204410/) (`pubmed-observation-pmid-18204410-2026-01-28-bf119eab6489`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Therapeutic possibility of 'Semax' for depression." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18204410-semax-v1.json SHA-256: 7c0f2b41dffe3dac67fc39cd79a78eedff2024842320d381d6892e7a8e33aeb3.